13 The serotoninergic system as a target for add-on treatment seems to be a promising approach in patients 14 Results. With no differences at baseline, there was a significant difference between the groups in Positive 26 and Negative Syndrome Scale (PANSS) positive subscale score (p 5 0.058) in favor of patients in the 27 treatment group at the endpoint. The PANSS positive subscore (p 5 0.0068) and Clinical Global 28 Impression-Severity (CGI-S) (p 5 0.048) score significantly changed only in the treatment group. Only in 29 the placebo group were significant changes in Calgary Depression Rating Scale (CDRS) total score 30 registered. The indices of attention tests at endpoint did not show differences between the groups, with the 31 exception of the scope of change in the results of the subtest VIII of the Wechsler Adult Intelligence Scale 32 (WAIS), which showed difference between the groups (p 5 0.02) and was significantly larger in the 33 treatment group. Only inside the study drug group, significant changes in selectivity and continuous 34 attention were observed regarding total correct responses (p 5 0.0038) and reaction time (p 5 0.058) in the 35 Continuous Attention Task (CAT) test. 
The compound was tested for anti-amnestic, anxio- Table 2 . 289 The only difference between the groups at endpoint Passive/apathetic social withdrawal significantly 317 decreased in both groups (study drug group: 318 p 5 0.027; placebo group: p 5 0.0027).
319
The cognitive indices that showed significant 320 changes in any group are shown in Table 3 . 321 It is notable that the Digit Symbol Coding scores in the 322 placebo group worsened, while no change was observed 323 in the AVN-211 (CD-008-0173) group. Selectivity of 324 attention and continuous attention improved in the 325 AVN-211 (CD-008-0173) group (effect size d 5 0.21), and 326 showed no change in the placebo group.
327
In analyzing the magnitude of changes in both 328 groups (differences of cognitive parameter between 329 baseline and endpoint visits), we find that the 330 The main goal of the present study was to reveal the 386 additional clinical effects of the selective 5HT6 AVN-211 387 (CD-008-0173) in patients with schizophrenia who were 388 stabilized on the antipsychotic medication. The results 389 showed that AVN-211 (CD-008-0173) improved a signi-390 ficant aspect of functioning of this group of schizophrenia 391 patients regarding residual psychotic symptoms. The 392 most important changes were decrease in the severity of 393 the residual delusions accompanied by a decrease in 394 overall severity of the disease (no changes in CGI-S score 395 in the placebo group and significant changes in the study 396 drug group). Similar data were obtained in the study 397 which showed that the combined treatment of clozapine 398 and aripiprazole had advantages over the monotherapy 399 of clozapine measured by CGI score. 51 
400
In relation to cognitive dysfunction, this study aimed 401 to assess the impact of the study drug (AVN-211) 402 attention in schizophrenia patients. This aspect of 403 cognitive dysfunction was chosen for two reasons: 404 First, attention was considered to be the only cognitive 405 target for antipsychotic treatment, and second, atten-406 tion is the most basic cognitive function. Some authors 407 consider that one of the aspects of attention, vigilance, 408 should be tested before all other more complicated 409 functions are examined. Our attempt to homogenize the group by the level of 411 attention dysfunction and gender was not fully 412 successful, as the individual variability of indices 413 regarding the cognitive tests was still very large. 414 Therefore, it was clear that we needed many more 415 patients to obtain reliable evidence that our pharmaco-416 logical agent really has an effect on patients' cognition. 417 More significant seem to be the results of CAT, where, 
